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CASE REPORT
A 32-year-old man presented with cough and bloody sputum. 
Computed tomography (CT) showed a mass in the S6 segment 
and diffuse consolidation throughout the lower lobe of the left 
lung. Transbronchial lung biopsy revealed adenocarcinoma 
(AC) with lymphangiosis. Immunohistochemistry (IHC) 
showed anaplastic lymphoma kinase (ALK) protein expres-
sion, and break-apart fluorescent in situ hybridization showed 
ALK gene rearrangement.
First-line chemotherapy with cisplatin and docetaxel 
was started in June 2010. After tumor progression, the patient 
was enrolled in the randomized trial (PROFILE 1007) and 
was allocated to the pemetrexed arm. Subsequently, he was 
enrolled in PROFILE 1005 trial to receive crizotinib in July 
2011 (Fig. 1A).
After a partial response was observed, a nodule in the 
S9 segment developed in size to 2 cm, in February 2012 
(Fig. 1B, C), and crizotinib was discontinued. CT scans 
performed after four cycles of carboplatin and gemcitabine 
showed a mixed response, with improvements in lymphade-
nopathy and lymphangiosis, but progression of the mass in 
S9. CT-guided core-needle biopsy revealed ALK-positive 
atypical cells, but it was impossible to distinguish histologi-
cal types because of degeneration and necrosis. Thereafter, 
carboplatin, paclitaxel, and bevacizumab were adminis-
tered, but the same mixed response was observed. The mass 
in S9 increased rapidly in size and reached 7 cm in August 
2012 (Fig. 1D).
Left lower lobectomy was performed in September 
2012. The primary tumor in S6 was diagnosed as 
AC-positive for thyroid transcription factor (TTF)-1 immu-
nostaining, whereas the tumor in S9 was TTF-1 nega-
tive sarcomatoid carcinoma (Figs. 2A-C, 3A-C). ALK 
was positive with IHC in both tumors, and fluorescent 
in situ hybridization revealed high-level gene amplifica-
tion of the ALK gene only in the sarcomatoid carcinoma 
(Figs. 2D, E, 3D, E). Reverse-transcriptase polymerase chain 
reaction (RT-PCR) revealed the same variant of echinoderm 
microtubule-associated protein-like 4-ALK (E13; A20). 
Moreover, in the sarcomatoid carcinoma, DNA sequencing 
revealed no additional resistance point mutations from ALK 
exon 20 to exon 23.
DISCUSSION
Non–small-cell lung cancers with ALK rearrangement are 
highly sensitive to the ALK kinase inhibitor crizotinib,1 but 
drug resistance invariably emerges. Morphological trans-
formation from AC to small-cell lung cancer represents one 
acquired resistance mechanism to epidermal growth factor 
receptor tyrosine kinase inhibitors and these tumors are sensi-
tive to standard small-cell lung cancer treatment.2 However, 
there are no reports on transformation resulting from crizo-
tinib in ALK-positive AC.
In this case, the sarcomatoid carcinoma showed high-
level gene amplification of the ALK gene, which is known 
to cause resistance to crizotinib.3 Interestingly, RT-PCR 
revealed the same variant of echinoderm microtubule-asso-
ciated protein-like 4-ALK in both AC and sarcomatoid carci-
noma and it indicated that these tumors have the same origin.
Epithelial-to-mesenchymal transition (EMT) is a 
process in which cells undergo a morphological change 
from the epithelial polarized phenotype to the mesenchymal 
phenotype and it has been related to the progression and 
metastasis of epithelial tumors.4 Moreover, EMT is known to 
cause acquired resistance to epidermal growth factor receptor-
tyrosine kinase inhibitor.2 To discuss the potential EMT, we 
performed E-cadherin and keratin staining as epithelial 
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markers, and vimentin staining as a mesenchymal marker in 
four specimens (Supplementary Fig. 1, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A432). The specimens 
include the following: precrizotinib specimen in S6, surgical 
specimen in S6, rebiopsied specimen in S9 after carboplatin 
and gemcitabine, and surgical specimen in S9. Rebiopsied 
specimen in S9 was unevaluable for IHC staining because of 
degeneration and necrosis. All the three evaluable specimens 
showed positive expression of vimentin and only surgical 
specimen in S9 showed negative for epithelial markers.
On the basis of these results of RT-PCR and IHC 
staining, the transformation from AC to sarcomatoid 
carcinoma could be interpreted as a kind of EMT. This 
transformation might represent a novel acquired resis-
tance mechanism to crizotinib, although there is another 
possibility that subsequent chemotherapies induced this 
transformation. Generally, sarcomatoid carcinomas show 
poor response to chemotherapy and are considered to be 
an aggressive subtype of non–small-cell lung cancer.5 
Therefore, surgery was considered a reasonable treatment 
strategy in this situation.
Repeated biopsies are encouraged to clarify the resis-
tance mechanism and to determine appropriate treatment. 
Surgical specimens are superior in terms of both quality and 
quantity. In addition, Weickhardt et al.6 reported even poten-
tial survival benefits of local therapy in combination with 
tyrosine kinase inhibitors after acquired resistance to erlotinib 
or crizotinib. Our case raises the possibility of additional roles 
of surgery in the era of targeted therapy.
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FIGURE 1.  CT scan evolution of the tumors. A, CT at baseline of crizotinib therapy revealed the primary tumor in S6 segment. 
B, CT at 6 months of crizotinib therapy showed significantly decreased tumor. C, A nodule in the S9 segment developed to 2 cm 
and crizotinib was discontinued. D, The tumor in S9 increased rapidly when compared with the tumor in S6. CT, computed 
tomography.
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FIGURE 2.  Pathological and genetic features of the primary tumor in S6 segment. A, Macroscopic appearance of surgical spec-
imen. Microscopic findings revealed (B) adenocarcinoma and (C) TTF-1 was positive. D, Immunohistochemistry showed ALK 
protein expression. E, Break-apart fluorescent in-situ hybridization showed ALK translocation. ALK, anaplastic lymphoma kinase.
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FIGURE 3.  Pathological and genetic features of the tumor in S9 segment. A, Macroscopic appearance of surgical specimen 
showed necrosis around the tumor. Microscopic findings revealed (B) sarcomatoid carcinoma and (C) TTF-1 was negative. D, 
Immunohistochemistry showed ALK protein expression. E, Fluorescent in-situ hybridization revealed high-level gene amplifica-
tion of the ALK fusion gene. Amplified ALK appeared as a cluster of isolated red signals. ALK, anaplastic lymphoma kinase.
